Abstract: A method of determining if a terrestrial test animal and/or test animal from which a product is derived has been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical includes: (a) determining a test methylation profile from genomic material contained in a biological sample obtained from the test animal and/or the animal-derived product; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal, where the control animal was not treated and/or is not currently undergoing treatment with at least one antibiotic and/or veterinary chemical, wherein a difference in the test methylation profile of (a) compared to the reference methylation profile from the control animal is indicative of the test animal having been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical.

Abstract: The invention relates to a sheet-like composite including as layers of a layer sequence, in a direction from an external side of the sheet-like composite to an internal side of the sheet-like composite, a) a carrier layer, b) a polymeric intermediate layer, and c) a barrier layer, where a graph of differential scanning calorimetry of the polymeric intermediate layer includes a peak A at a temperature TA and a peak B at a temperature TB, where the temperature TB is more than the temperature TA, where a width of the peak B is less by at least 3° C. than a width of the peak A. The invention further relates to a container precursor and to a closed container including the sheet-like composite, and also to a process by which the sheet-like composite is obtainable, and to a use of the sheet-like composite.

Abstract: The invention pertains to an in vitro method for detecting avian intestinal dysbiosis, the method comprising determining the presence and/or level of isoleucyl-arginine (C12H25O3N5) or isomers thereof in avian sample material wherein the presence and/or an increased level of isoleucyl-arginine (C12H25O3N5) or isomers thereof in comparison to a non-affected control is indicative for avian intestinal dysbiosis.

Abstract: A method of determining if an aquatic test animal and/or test animal from which a product is derived has been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical includes: (a) determining a test methylation profile from genomic material contained in a biological sample obtained from the test animal and/or animal-derived product; and (b) comparing the test methylation profile obtained from (a) with a reference methylation profile obtained from a control animal of the same biological taxon of the test animal, where the control animal was not treated and/or is not currently undergoing treatment with at least one antibiotic and/or veterinary chemical, wherein a difference in the test methylation profile of (a) compared to the reference methylation profile from the control animal is indicative of the test animal having been treated and/or is currently undergoing treatment with at least one antibiotic and/or veterinary chemical.

Abstract: The present invention relates to Bacillus strains with improved outgrowth and/or germination characteristics and their use in feed, food and pharmaceutical compositions.

Abstract: The present invention relates to a liquid-tight container comprising a container wall which surrounds a container interior at least in part, wherein: a jacket element and a first end element are connected to one another and each form a portion of the container wall; wherein the jacket element delimits the container interior in a transverse direction extending from the inside to the outside in relation to the container interior, and comprises a rim portion having a first edge; wherein the first end element delimits the container interior at a first end of the liquid-tight container in a longitudinal direction extending along the length of the container, and comprises a further edge which points in the longitudinal direction; wherein the rim portion a. is located at the first end of the container, and b. encloses the further edge counter to the transverse direction from the outside to the inside in such a way that i.

Abstract: The invention discloses preparations for use in enhancing formation of short-chain fatty acids (SCFAs) in a subject for treating or preventing a disease or disorder comprising at least one omega-3 fatty acid salt having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, wherein the omega-3 fatty acid is selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and a colon-specific delivery system.

Abstract: The invention relates to a container comprising a container wall at least partially enclosing a container interior, and a first joining element; wherein a jacket element and a first end element each form a region of the container wall; wherein at least one first plane running parallel to the length of the container through the container interior comprises a first joining layer sequence, over the entire lateral extent of which, with respect to the first joining layer sequence, the jacket element, the first joining element and the first end element directly follow one another as layers; wherein the first joining element has a first surface contacting the first end element and a second surface contacting the jacket element; wherein an imaginary first straight line connects both end points of a first line formed in the at least one first plane by the first surface and lying within the first joining layer sequence; wherein an imaginary second straight line connects both end points of a second line formed in the at

Abstract: A synbiotic preparation may include at least one probiotic strain and at least one amino acid or derivative thereof selected from glutamine, glutamic acid or salts thereof, conjugated glutamine, or oligopeptides of 2-10 amino acid units in length, wherein the amino acid units may be natural amino acids, and at least one amino acid unit being a glutamine or glutamic acid unit.

Abstract: The subject of the present invention are microorganisms with reduced competence and compositions containing such microorganisms, in particular feed, food and pharmaceutical compositions.

Abstract: Bacillaene producing bacteria and compositions containing bacillaene producing bacteria can be used as probiotic feed ingredients. Bacillaene or derivatives thereof can be used for treating bacterial diseases.

Abstract: The present invention pertains to an in vitro method for detecting intestinal barrier failure in an avian population, the method comprising the following steps: a) collecting a pooled fecal sample deriving from an avian population and b) determining the amount of at least one protein marker contained in said sample; wherein the at least one protein marker comprises or consists of an acute phase protein or a functional fragment thereof, and wherein an increased amount of said at least one protein marker contained in said sample versus a reference sample indicates intestinal barrier failure.

Abstract: The invention provides a method for classifying the gut inflammation status of an avian subject or of a group of avian subjects to be tested, the method comprising the comparison of the average methylation levels within a panel of pre-selected LMRs in the genomic DNA isolated from gut sample material deriving from the individual avian subject or of the group of avian subjects to be tested with the average methylation levels of the same panel of LMRs in the genomic DNA pertaining to one or more reference samples having a negative gut inflammation status.

Abstract: The present invention relates to a method for detecting C. perfringens induced diseases in animals, the method comprising: a) collecting sample material of a specific animal or of a specific group of animals at consecutive points in time; b) determining the amount of a first marker and a second marker contained in the sample material; and c) determining the ratio of the first marker to the second marker contained in the sample material; wherein the first marker comprises a polynucleotide sequence being specific for the C. perfringens sub-species inducing the targeted disease; and the second marker comprises a polynucleotide being specific for the species C. perfringens; and wherein an increase in the ratio of the first marker to the second marker in the analyzed sample material over time is an indication of the targeted disease.

Abstract: A preparation comprising probiotic strains belonging to the genera Bacillus sp., Lactobacillus sp., optionally Pediococcus sp. as viable cells or cytoplasmic extract thereof, and proteases, wherein the strains can degrade peptide sequences of gliadins. The preparation can be used to produce gluten-free foods from gluten-containing cereals or to treat gluten-related disorders.

Abstract: The invention pertains to an in vitro method for predicting the chronological age of healthy Galliformes, the method comprising the steps of: (a.) obtaining genomic DNA from biological sample material deriving from the Galliformes subject or from the Galliformes population to be tested, (b.) determining the methylation level of a set of specific CpG sites in the genomic Galliformes DNA obtained in step (a.), and (c.

Abstract: The invention concerns new Bacillus strains which are able to degrade effectively inorganic nitrogen compounds and are further able to inhibit the growth of pathogens of aquatic animals.

Abstract: A computer-implemented method of establishing an epigenetic clock for an avian species including: (a) identifying and determining methylation levels of specific CpG sites within a genomic DNA obtained from a plurality of different biological sample materials deriving from the avian species and representing specific time points within a chronological lifespan of the avian species, (b) excluding all CpG sites associated with single nucleotide polymorphisms (SNPs) from the CpG sites identified in (a), (c) excluding all CpG sites located on sex chromosomes from the CpG sites obtained in (b), (d) performing a tissue-specific normalization for the CpG sites obtained in (c), and (e) correlating the CpG methylation levels of the CpG sites obtained in (d) with chronological age with a penalized regression model.

Abstract: This invention concerns a process to identify consortia of probiotic strains belonging to e.g. the genera Lactobacillus, Bacillus, Pediococcus, and Weissella that can be used in preparations for food supplement, food production, and pharmaceutical applications with the intention to execute a safe and rapid degradation of gluten to non-toxic, non-immunogenic digests.

Abstract: The invention discloses preparations for use in enhancing formation of short-chain fatty acids (SCFAs) in a subject for treating or preventing a disease or disorder comprising at least one omega-3 fatty acid salt having an organic counter ion selected from lysine, arginine, ornithine, choline and mixtures of the same, wherein the omega-3 fatty acid is selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and a colon-specific delivery system.